CMV Drug Resistance Test

Helping Pharma companies develop Precision medicine using Clinical Data & AI.

What is CMV Drug Resistance Testing?

Cytomegalovirus (CMV) is a common virus that can cause severe complications in immunocompromised individuals, such as transplant recipients or those with HIV/AIDS. When standard antiviral treatments fail, it is often due to genetic mutations conferring drug resistance. GeneHealth’s CMV Drug Resistance Test utilizes advanced Next-Generation Sequencing (NGS) to rapidly identify specific mutations in the CMV genome, empowering clinicians to tailor targeted antiviral therapies effectively.

Book a Test Now →

Gene Coverage in CMV Drug Resistance Testing

Gene	Function / Resistance Profile
UL97	Associated with Ganciclovir and Valganciclovir resistance.
UL54	Associated with Foscarnet and Cidofovir resistance (DNA Polymerase mutations).
UL56	Associated with Letermovir resistance.

Key Benefits of the Test

Guides appropriate and targeted antiviral drug selection.
Prevents disease progression in refractory or recurrent CMV infections.
Helps customize antiviral dosing and treatment duration.
Improves overall patient outcomes, particularly in vulnerable post-transplant scenarios.

Specifications

Test Code: GH-CMV-01

Methodology: Next Generation Sequencing (NGS).

Sample Type: Whole blood (3-5 ml in EDTA tube), Plasma (1-2ml), CSF, Urine, or Amniotic fluid.

Turnaround Time: 14 working days.

Diseases & Disorders Detected

Clinical scenarios where CMV resistance testing is crucial.

Applicable for Diseases

Cytomegalovirus (CMV) Infection
Congenital CMV
CMV Retinitis
CMV Pneumonia
CMV Gastroenteritis

Applicable for Disorders

Immunosuppression (e.g., Solid Organ or Stem Cell Transplant recipients, HIV/AIDS)
Primary Immunodeficiency
Post-transplant Viral Complications

Key Highlights of GeneHealth’s CMV Test

High Precision

Advanced NGS technology detects even low-frequency genetic mutations conferring resistance to standard antiviral medications.

Essential for High-Risk Patients

Critical for transplant recipients and immunocompromised individuals, ensuring effective viral suppression and reducing the risk of severe complications.

Comprehensive Coverage

Identifies mutations across key viral genes (UL97, UL54, and UL56) that are heavily correlated with drug resistance in CMV patients.